{"disease":{"id":"stage-iii-adrenal-cortex-carcinoma","name":"stage iii adrenal cortex carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03583710","title":"Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06006013","title":"Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03370718","title":"Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02720484","title":"Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Northwestern University","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}